HLA-E and cancer: Noncanonical peptides display higher sequence heterogeneity as compared to classical HLA-leader-derived peptides presented by HLA-E, can be recognized by specific T cells through their TCR, and have been identified in the context of various infectious diseases and potentially cancers (46, 48).